April 13, 2015 / 1:58 PM / 2 years ago

BUZZ-Aeterna Zentaris Inc: To begin late-stage study on hormone drug

** Canadian drug developer's U.S.-listed shares up 6 pct at $0.54; Toronto-listed shares up 6.15 pct at C$0.69

** Says plans to conduct confirmatory study on hormone deficiency drug-test after meeting with U.S. Food and Drug Administration

** FDA rejected the test on Nov. 6 last year

** Up to Friday's close, U.S. shares had fallen 60 pct since test was rejected

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below